National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Enzalutamide (Xtandi®) for nmCRPC. HTA ID: 18056

Enzalutamide (Xtandi®) is indicated for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).


NCPE Assessment Process Complete
Rapid review commissioned 18/12/2018
Rapid review completed 06/02/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of enzalutamide in combination with ADT compared with the current standard of care
Full pharmacoeconomic assessment commissioned by HSE 13/02/2019
Pre-submission consultation with Applicant 11/06/2019
Full HTA submission received from Applicant 30/04/2021
Current Status Full HTA submission received from Applicant